Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

2017486 citationsJournal Articlehybrid Open Access

Authors

Bayer PLC and BTG PLC.

Good health and well-being

Published in: The Lancet. Gastroenterology & hepatology

Volume 2, Issue 8, pp. 565-575

Field-Weighted Citation Impact: 23.13